[{"id":"b2d58859-e4a8-407a-abe5-c970d72bf8b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05380882","created_at":"2022-05-19T12:56:57.386Z","updated_at":"2024-07-02T16:36:10.152Z","phase":"Phase 1","brief_title":"Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers","source_id_and_acronym":"NCT05380882","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB2930"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-05-19"}]